@entity901 and @entity1487 hepatic infusion with lipiodolized chemoembolization in large XXXX .

@entity901 @entity1 @entity295 @entity1087 @entity2363 @entity1578 @entity4831 @entity160 @entity1349 @entity157 @entity1054 @entity1487
AIM: To investigate transarterial chemoembolization (TACE) with hepatic infusion of @entity901 and @entity1487 and @entity4831 chemoembolization in large @entity157 ( @entity157 ). METHODS: In this retrospective study, 132 @entity1 with unresectable HCCs larger than 10 cm were treated with hepatic infusion of @entity901 and @entity1487 followed by @entity4831 chemoembolization. The primary endpoint was @entity1349 ( @entity1349 ). Sixteen-week disease-control rate, @entity1054 ( @entity1054 ), and major complications were also studied. Univariate and multivariate analyses were performed to identify prognostic factors affecting @entity1349 and @entity1054 . RESULTS: A total of 319 procedures were performed in the 132 @entity1 . Eleven (8.3%) @entity1 received radical resection following TACE treatment (median time to initial TACE 4.3    2.3 mo). The median @entity1349 and @entity1054 were 10.3 and 3.0 mo respectively, with a 50.0% 16-wk disease-control rate. Major complications were encountered in 6.0% (8/132) of @entity1 following TACE and included serious @entity1087 in 1.5% (2/132) @entity1 , @entity2363 in 1.5% (2/132), and @entity1578 in 3.0% (4/132). One @entity1 died within one month due to serious @entity1578 and @entity295 after receiving the second TACE. The risk factor associated with @entity1054 was baseline @entity160 level, and vascular invasion was an independent factor related to @entity1349 . CONCLUSION: Hepatic infusion of @entity901 and @entity1487 followed by lipiodolized-chemoembolization is a safe and promising treatment for @entity1 with HCCs larger than 10 cm in diameter.
